Vassyl Lonchyna to Prospective Studies
This is a "connection" page, showing publications Vassyl Lonchyna has written about Prospective Studies.
Connection Strength
0.008
-
Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Southwest Oncology Group. Ann Thorac Surg. 1994 Aug; 58(2):290-4; discussion 294-5.
Score: 0.004
-
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg. 1993 Jan; 105(1):97-104; discussion 104-6.
Score: 0.004